1	Title page				
2					
3	A non-muscle myosin heav	y chain 9 genetic variant is associated with graft failure following			
4	kidney transplantation.				
5	Felix Poppelaars ¹ , Siawosh k	K. Eskandari ¹ , Jeffrey Damman ² , Marc A. Seelen ¹ , Bernardo Faria ^{1,3,*} ,			
6	Mariana Gaya da Costa ^{1,4,*}				
7					
8	* Authors contributed equally				
9					
10	¹ Department of Internal Medicir	ne, Division of Nephrology, University Medical Center Groningen, University			
11	of Groningen, Groningen, The N	letherlands.			
12	² Department of Pathology, Eras	mus Medical Center, University Medical Center, Rotterdam, The Netherlands.			
13	³ Nephrology and Infectious Disease R&D Group, INEB, Institute of Investigation and Innovation in Health				
14	(i3S), University of Porto, Porto, Portugal.				
15	⁴ Department of Anesthesiology, University of Groningen, University Medical Center Groningen, Groningen,				
16	The Netherlands.				
17					
18	Running head:	A genetic variant in MYH9 associates with graft loss			
19	Keywords:	Molecular motor proteins, kidney transplantation, nephrology, genetics.			
20					
21	Word Title:	18 words			
22	Running head:	50			
23	Word count abstract	288 words			
24	Word count body:	2.883 words			
25	Number of pages:	34			
26	Number of figures:	4			
27	Number of tables:	5			
28	References:	32			

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

1 Address for Correspondence:

- 2 Felix Poppelaars, M.D./Ph.D.
- 3 University Medical Center Groningen
- 4 Department of Internal Medicine, Division of Nephrology, AA53
- 5 Postbus 196
- 6 9700 AD Groningen, The Netherlands
- 7 Phone: +31 50 3610544
- 8 Fax: +31 50 3619320
- 9 E-Mail: <u>f.poppelaars@umcg.nl</u>
- 10

1 Abbreviations

2	APOL1	Apolipoprotein L1 gene
3	BPAR	Biopsy-proven acute rejection
4	CIT	Cold ischemia time
5	СКД	Chronic kidney disease
6	DBD	Donation after circulatory death
7	DCD	Donation after brain death
8	DGF	Delayed graft function
9	ESKD	End-stage kidney disease
10	HLA	Human leukocyte antigen
11	HR	Hazard ratio
12	МҮН9	Myosin heavy chain 9 gene
13	PRA	Panel-reactive antibody
14	OR	Odds ratio
15	SNP	Single-nucleotide polymorphism
16	WIT	Warm ischemia time
17		

1 Key points

- In recipients, the *MYH9* SNP was associated with delayed graft function and biopsy-proven acute
- 3 rejection after kidney transplantation, although the significance was lost in multivariable analysis.
- Presence of the *MYH9* variant in both the donor and recipient significantly associated with long-
- 5 term kidney allograft survival in multivariable analysis.
- Our present findings suggests that matching donor-recipient transplant pairs based on the *MYH9*
- 7 polymorphism may attenuate the risk of graft loss.
- 8

1 Abstract

2

3 Background

Despite current matching efforts to identify optimal donor-recipient pairs in kidney transplantation, alloimmunity remains a major proponent of late transplant failure. While kidney allocation based on human leukocyte antigen (HLA) matching has markedly prolonged short-term graft survival, new data suggests that additional genetic parameters in donor-recipient matching could help improve the longterm outcomes. Here, we studied the impact of a recently discovered non-muscle myosin heavy chain 9 gene (*MYH9*) polymorphism on kidney allograft failure.
Methods

11 We conducted a prospective observational cohort study, analyzing the DNA of 1,271 kidney donor-

12 recipient transplant pairs from a single academic hospital for the *MYH9* rs11089788 C>A polymorphism.

13 The association of the *MYH9* genotype with the risk of graft failure (primary outcome), biopsy-proven

14 acute rejection (BPAR), and delayed graft function (DGF) (secondary outcomes) were determined.

15 Results

16 The MYH9 polymorphism in the donor was not associated with 15-year death-censored kidney graft 17 survival, whereas a trend was seen for the association between the MYH9 polymorphism in the recipient 18 and graft failure (recessive model, P=0.056). Having the AA-genotype of the MYH9 polymorphism in 19 recipients was associated with a higher risk of DGF (P=0.031) and BPAR (P=0.021), although the 20 significance was lost after adjustment for potential confounders (P=0.15 and P=0.10, respectively). The 21 combined presence of the MYH9 polymorphism in donor-recipient pairs was significantly associated 22 with long-term kidney allograft survival (P=0.036), in which recipients with an AA-genotype receiving a 23 graft with an AA-genotype had the worst outcome. After adjustment for covariates, this combined 24 genotype remained significantly associated with 15-year death-censored kidney graft survival (HR 1.68, 25 95%-CI: 1.05 - 2.70, P=0.031).

26 Conclusions

27 Our results reveal that recipients with an AA-genotype *MYH9* polymorphism receiving a donor kidney

with an AA-genotype, have a significantly elevated risk of graft failure after kidney transplantation.

1 Introduction

2 Despite the excellent short-term outcomes following solid organ transplantation, the long-term survival 3 of kidney transplants has only negligibly improved in recent years.¹ As a consequence, one out of five 4 patients on the waitlist for kidney transplantation are candidates whose previous grafts failed.² 5 Maximizing the long-term outcomes of transplantation and preventing re-transplantation is, thus, 6 paramount-not only for improving transplant recipients' outcomes, but also for reducing waitlist 7 pressures. Among the many drivers of late graft loss, alloimmunity, otherwise known as host anti-donor 8 immune responses, remains to be the preeminent cause, notably, despite efforts to optimally match 9 donor-recipient pairs.^{3,4} Recently, there are signs of a paradigm shift in the transplant field, with 10 suggestions that allograft matching efforts should be updated to include novel genetic markers that 11 better ensure long-term graft survival after kidney transplantation.^{5,6}

12 In this regard, non-muscle myosin heavy chain II-A (MHCII-A), encoded by the myosin heavy 13 chain 9 gene (MYH9), is a target of particular interest (Fig. 1A). Non-muscle MHCII-A is a ubiquitously 14 expressed contractile protein involved in a myriad of processes ranging from cell division and adhesion 15 to providing cytoskeletal support.⁷ Mutations in the *MYH9* cause a complex set of disorders, known as 16 MYH9-related diseases, that can affect every system in the body but are characterized by congenital 17 thrombocytopenia, giant platelets and leucocyte inclusions.⁷ Although non-muscle MHCII-A is 18 expressed by a variety of cell types, the podocyte lineage in particular, expressed high levels of this 19 protein.⁷ Unsurprisingly, patients with MYH9-related disorders can clinically present with persistent 20 proteinuria and a progressive decline in kidney function leading to end-stage kidney disease (ESKD).^{7,8} 21 Subsequent studies linked common MYH9 polymorphisms to an increased risk of developing focal 22 segmental glomerulosclerosis and non-diabetic ESKD.^{9,10} However, it is worthy to note that these 23 associations were later shown to be dependent on a strong linkage disequilibrium of these MYH9 24 polymorphisms with variants in the apolipoprotein L1 gene (APOL1).^{7,11} Still, there are studies that show 25 an association between MYH9 polymorphisms and chronic kidney disease (CKD) independently of 26 linkage with APOL1, suggesting a potential role for MYH9 polymorphisms in the pathogenesis of 27 ESKD.^{12,13}

In a recent genome-wide linkage analysis, a significant association between the *MYH9* rs11089788 polymorphism and kidney function was identified in a meta-analysis of three European populations.¹⁴ This *MYH9* polymorphism was additionally found to be significantly associated with

progressive loss of kidney function in other cohorts.^{13,15} Importantly, the associations between *MYH9*rs11089788 and kidney function could not be explained by linkage disequilibrium with *APOL1*.¹⁵
Here, we investigated the impact of the recently discovered rs11089788 *MYH9* polymorphism
on long-term graft survival in the context of kidney transplantation (Fig. 1B). As a secondary outcome,
we also assessed the association of this polymorphism with biopsy-proven acute rejection (BPAR) and
delayed graft function (DGF).

1 Materials and Methods

2

3 Patient selection and study end-point

4 Patients receiving a single kidney transplantation at the University Medical Center Groningen (UMCG) 5 in the Netherlands were recruited between March 1993 and February 2008. 1,271 of the 1,430 screened 6 donor-recipient kidney transplant pairs were included in the current study as previously reported.¹⁶⁻²¹ 7 Ethical approval for this study and the study protocol was given by the Institutional Review Board of the 8 University Medical Center Groningen in Groningen, The Netherlands (Medical Ethical Committee 9 2014/077). The study protocol adhered to the Declaration of Helsinki. All subjects provided written 10 informed consent. Reasons for exclusion of patients in this study were technical complications during 11 surgery, lack of DNA, loss of follow-up, or re-transplantation at the time of recruitment. The primary 12 endpoint of this study was long-term death-censored graft survival and the maximum follow-up period 13 was 15 years. Graft failure was defined as the need for dialysis and/or re-transplantation. Secondary 14 endpoints included: The occurrence of delayed graft function (DGF; described by the United Network 15 for Organ Sharing as, "The need for at least one dialysis treatment in the first week after kidney 16 transplantation,") and biopsy-proven acute rejection (BPAR; based on the Banff '07 classification).

17

18 DNA extraction and *MYH9* genotyping

19 Peripheral blood mononuclear cells from blood or splenocytes were obtained from both the donor and 20 recipient. DNA isolation was done with a commercial kit according to the manufacturer's instructions 21 and stored at -80°C. Genotyping of the single nucleotide polymorphism (SNP) was performed using the 22 Illumina VeraCode GoldenGate Assay kit as per the manufacturer's instructions (Illumina, San Diego, 23 CA, USA). We opted for the MYH9 rs11089788 C>A SNP, which has previously been associated with 24 kidney function in healthy individuals and with disease progression in patients with CKD.^{13–15} Genotype 25 clustering and calling were performed using BeadStudio Software (Illumina). The overall genotype 26 success rate was 99.9% and only two samples were excluded from subsequent analyses because of a 27 missing call rate.

28

29 Statistical analysis

1 SPSS software version 25 (SPSS Inc, Chicago, IL, USA) was used for our statistical analyses. Data 2 are presented as the total number of patients with percentage [n (%)] for nominal variables, mean ± 3 standard deviation for parametric variables, and median [IQR] for non-parametric variables. Differences 4 among groups were tested with the χ^2 test for categorical variables or Student's *t*-test for normally 5 distributed variables, and the Mann-Whitney U-test for not-normally divided variables, respectively. The 6 Log-rank test was used to test for differences in kidney allograft survival or rejection-free survival among 7 the different genotypes. Logistic regression was used to assess the association of the MYH9 8 polymorphism with DGF. Univariable analysis was used to examine the association of the MYH9 9 polymorphism, recipient, donor, and transplant characteristics with BPAR as well as death-censored 10 graft survival. Significant associations in univariable analyses were then assessed in a multivariable 11 Cox regression. Two-tailed tests were regarded as significant at P < 0.05.

1 Results

2

3 Study population and determinants of graft failure

4 All patients who underwent a single kidney transplantation at the University Medical Center Groningen 5 were recruited for this study (n=1,271). Baseline patient characteristics are shown in Table 1. During 6 the mean study period of 6.2 years ± 4.2, 215 of 1,271 kidney transplant recipients (16.9%) developed 7 graft failure. The main reason for graft failure was rejection (n = 126, containing acute rejection, 8 transplant glomerulopathy, and chronic antibody-mediated rejection). Other causes for graft loss were 9 surgical complications (n = 33), relapse of the original kidney disease (n = 16), other causes (n = 16), 10 vascular disease (n = 12), and unknown cause (n = 12). In univariable analysis, DGF, recipient age, 11 recipient blood type (AB vs others), donor type (living vs cadaveric), donor age, donor blood type (AB 12 vs others), cold ischemia time, warm ischemia time, use of cyclosporin, and use of corticosteroids were 13 all associated with graft failure (P < 0.05).

14

15 **Distribution of the** *MYH***9 polymorphism**

16 The observed genotypic frequencies of the MYH9 SNP (rs11089788 C>A) did not differ between donors 17 (n = 1269; CC, 25.0%; CA, 54.1%; AA, 20.9%) and recipients (n = 1269; CC, 25.7%; CA, 50.0%; AA, 18 24.3%) (P = 0.07). The distribution of the SNP was in Hardy–Weinberg equilibrium. Compared to the 19 1000 genomes project, the genotypic frequencies of the MYH9 polymorphism in recipients and donors 20 were significantly different (P < 0.001).²² In both recipients and donors, the A-allele of the MYH9 SNP 21 was more prevalent than the reported allele and genotype frequencies in the 1000 genomes project. 22 The percentage of kidney allografts with DGF significantly differed based on the recipient MYH9 23 genotype (33.7% in CC, 29.6% in CA, 37.7% in AA, P = 0.041), but not for the donor MYH9 genotype 24 (P = 0.93). For further analysis, heterozygotes (CA) and homozygotes (CC)-genotypes were combined 25 into one group (CA/CC). In logistic regression, recipients carrying the AA-genotype of the MYH9 26 polymorphism had a significantly elevated risk of DGF (OR = 1.34 compared to CA/CC-genotypes; 95%-27 CI: 1.03 - 1.76; P = 0.031). In multivariable logistic regression, the AA-genotype of the MYH9 28 polymorphism in recipients was no longer significantly associated with the occurrence of DGF (OR = 29 1.26 compared to CA/CC-genotypes; 95%-CI: 0.92 – 1.72; P=0.15, Table 2). There was no difference 30 in the overall BPAR frequency among the MYH9 genotypes in the donor (34.7% in CC, 33.0% in CA, 1 35.8% in AA, P = 0.69). In contrast, the distribution of the MYH9 polymorphism in the recipient showed 2 a trend towards a higher risk of BPAR (31.6% in CC, 32.4% in CA, 39.3% in AA, P = 0.068, Fig. 2A). A 3 significant association was found with BPAR when the AA-genotype of the MYH9 polymorphism in the 4 recipient was compared to CA- and CC-genotypes (39.3% in AA versus 32.2% in CA/CC, P = 0.021, 5 Fig. 2B). In multivariable Cox regression, the AA-genotype of the MYH9 polymorphism in recipients was 6 no longer significantly associated with the occurrence of BPAR (HR = 1.22 compared to CA/CC-7 genotypes; 95%-CI: 0.97 – 1.54; P=0.10, Table 3). In summary, although the AA-genotype of the MYH9 8 polymorphism in recipients was associated with DGF and BPAR, the significance was lost when 9 correcting for potential confounders.

10

11 Long-term kidney graft survival based on the *MYH9* genotypes

12 Kaplan–Meier survival analysis demonstrated no association between the MYH9 SNP in the recipient 13 or the donor and death-censored kidney graft survival (Figure 3). However, a trend was seen for a 14 heightened rate of graft failure in the recipients with an AA-genotype of the MYH9 polymorphism 15 compared to CA- and CC-genotypes (graft loss: 33.2% in AA versus 24.1% in CA/CC, P = 0.056, Fig. 16 3B). Next, donor-recipient pairs were separated into four groups according to the presence or absence 17 of the AA-genotype of the MYH9 polymorphism in the donor and recipient. Kaplan-Meier survival 18 analyses showed a significant difference in graft failure rates among the four groups (P = 0.036, Fig. 19 4A). Intriguingly, the AA-genotype of the MYH9 polymorphism in the donor seemed to have a marginal 20 positive impact on graft survival, whereas the AA-genotype in the recipient had a modest detrimental 21 impact compared to donor-recipient pairs with the combined CC/CA-genotype. Recipients with an AA-22 genotype receiving a graft with an AA-genotype had the worst outcome. This combined genotype was 23 identified in 6.3% of the donor-recipient pairs. Moreover, the significant association with graft failure 24 increased when the combined AA-genotype of the MYH9 polymorphism in donor-recipient pairs was 25 compared to the other groups (P = 0.011, Fig. 4B). The cumulative 15-year death-censored kidney 26 allograft survival was 50.4% in this combined AA-genotype group and 74.9% in the reference group, 27 respectively. These data suggest that matching donor-recipient pairs on the MYH9 polymorphism may 28 impact long-term graft survival in kidney transplantation.

29

30 Regression analysis for the *MYH9* polymorphism in donor-recipient pairs and graft failure

1 Finally, we investigated if the MYH9 variant in donor-recipient pairs is an independent risk factor for 2 graft failure. In univariable analysis, the combined AA-genotype of the MYH9 SNP in donor-recipient 3 pairs was associated with a hazard ratio of 1.78 (95%-CI: 1.13 - 2.79; P = 0.012) for graft failure after 4 complete follow-up. Subsequently, multivariable analysis was performed to adjust for potential 5 confounders, including donor and patient characteristics as well as transplant variables (Table 4). In 6 these Cox regression analyses, the combined AA-genotype of the MYH9 SNP in donor-recipient pairs 7 remained significantly associated with graft failure. Lastly, we performed a multivariable Cox regression 8 analysis using all variables that were significantly associated with graft failure in univariable analysis 9 (Table 5). In this model, the MYH9 SNP (rs11089788) in donor-recipient pairs, the occurrence of DGF, 10 recipient age, and donor age were all significantly associated with graft loss. After adjustment, the 11 hazard ratio for graft failure of the combined AA-genotype for the MYH9 SNP in donor-recipient pairs 12 was 1.68 (95% CI: 1.05 – 2.70, P = 0.031). In conclusion, our results reveal that recipients with an AA-13 genotype of the MYH9 SNP receiving a kidney allograft with an AA-genotype have a significantly 14 elevated risk of graft failure after kidney transplantation.

1 Discussion

2 A multitude of strategies can be pursued to improve the long-term outcomes after kidney transplantation, 3 ranging from the development of novel drugs that can pull the brakes on allo-immune cascades, to the 4 refinement of donor-recipient matching systems to minimize the severity of allograft recognition. 5 Regarding allograft matching, HLA-centric systems remains the cornerstone of allocating kidney 6 allografts—although a paradigm shift in the approach to donor-recipient matching is urgently needed.²³ 7 Genetic analyses in transplantation provides a particularly unique opportunity for the development of 8 innovative strategies that can improve donor-recipient pairing and drive personalized medicine, in part 9 by enabling individualized risk stratification.^{24,25} Presently, we report the impact of a recently discovered 10 polymorphism in MYH9 on long-term kidney allograft survival. The key finding of our study is that 11 recipients with an AA-genotype of the MYH9 rs11089788 variant receiving a kidney allograft with an 12 AA-genotype of the same variant, have a significantly elevated risk of developing graft loss. In contrast, 13 no association for the MYH9 polymorphism with long-term allograft survival was found in either the 14 recipient or donor when assessed individually. Hence, our study provides evidence that matching 15 recipients with donor kidneys based on the MYH9 polymorphism may well impact the risk of graft loss.

16 To our knowledge, our study is the first to show an association between this MYH9 variant and 17 long-term graft survival after kidney transplantation. Specifically, we found that the combined AA-18 genotype in donor-recipient pairs nearly doubled the risk of graft failure. Genome-wide linkage analysis 19 recently highlighted the MYH9 rs11089788 polymorphism as a top variant for kidney function in a meta-20 analysis of three European populations.¹⁴ In accordance with our results, the C-allele of the MYH9 21 rs11089788 polymorphism was consistently associated with better kidney function in healthy 22 Europeans.¹⁴ Furthermore, in a Chinese cohort of IgA nephropathy patients, the A-allele of this variant 23 was associated with hastened progression to kidney failure.¹³ Other groups, however, did not 24 recapitulate an association between this MYH9 variant and kidney outcomes.^{26,27} In particular, 25 Franceschini and colleagues found no relationship between the MYH9 rs11089788 polymorphism and 26 kidney function or CKD in native Americans.²⁷ Importantly, we found no relationship of this MYH9 variant 27 in the recipient or the donor alone with death-censored kidney graft survival either. Our findings, thus, 28 suggest that only donor-recipient interactions in MYH9 may lead to kidney function decline after renal 29 transplantation.

1 The importance of the MYH9 for the kidney has been investigated by several group but remains 2 controversial. Initial reports linked certain variants in the MYH9 to a greater risk of CKD.^{9,10} Later studies 3 uncovered that this association was based on the strong linkage disequilibrium between MYH9 variants 4 and variants in APOL1.^{7,11} Nonetheless, patients with rare mutations in MYH9 leading to MYH9-related 5 diseases often present with signs of CKD and can develop ESKD.^{7,8} In line with these results, 6 heterozygous mice with mutations in *Myh9* manifest similar pathological kidney phenotypes as humans 7 with MYH9-related diseases, including proteinuria, focal segmental glomerulosclerosis, and CKD.²⁸ 8 Intriguingly, Myh9 knockdown in zebrafish lead to the malformation and dysfunction of their glomeruli.²⁹ 9 More specifically, these zebrafish failed to correctly develop the glomerular capillary structure, lacking 10 fenestration in the endothelial cells and having an absence or reduced number of mesangial cells 11 together with irregular thickening of the glomerular basement membrane.²⁹ Although kidney clearance 12 experiments showed that the glomerular barrier function remained unaltered, glomerular filtration in 13 these zebrafish was significantly reduced.²⁹ Altogether, these findings attest a key role for *MYH9* and 14 non-muscle myosin heavy chain II-A in kidney development and physiology.

15 In humans, non-muscle myosin II-A, whose heavy chains are encoded by MYH9, is expressed 16 in the podocytes, tubular cells, endothelial cells of the peritubular capillaries, interlobular arteries, and 17 arterioles.³⁰ A potential mechanism underpinning the association between MYH9 polymorphism and 18 graft failure would likely be dependent on kidney-expressed non-muscle myosin heavy chain II-A. On 19 the basis of our findings, however, alternative mechanisms may be more probable. Firstly, in the 20 recipients a trend was found for the association between the MYH9 polymorphism and graft loss, while 21 there was no association in the donor genotypes. Secondly, the AA-genotype of the MYH9 variant in 22 the recipient, but not the donor, was associated with BPAR and DGF, although significance was lost 23 after adjusting for potential confounders. Lastly, in the genotypic analysis of the donor-recipient pairs, 24 the isolated donor AA-genotype was marginally protective while the isolated AA-genotype in the 25 recipient had a modest detrimental effect on graft survival. Additional evidence supporting a systemic 26 role of the MYH9 variant in determining kidney allograft outcomes is provided by case report of a patient 27 with focal segmental glomerulosclerosis, where proteinuria rapidly recurred following a deceased donor kidney transplantation that therapeutically responded to plasmapheresis.³¹ Moreover, the fact that 28 29 donor-recipient pairs with the combined AA-genotype of the MYH9 variant had the highest risk of graft 30 loss in our population, suggests both donor-recipient interactions in MYH9 with perhaps a leading role

for extra-renal expressed non-muscle myosin heavy chain II-A. A case report of two kidney transplants
 in pediatric patients suggested a similar donor-recipient *MYH9* interaction.³²

3 Overall, there are several limitations to our study that warrant consideration. First, our study 4 design is observational in nature and thus cannot determine whether associations are based on 5 causality. Therefore, we cannot exclude the possibility that the MYH9 rs11089788 variant is a tag SNP 6 in the neighboring APOL1 to APOL6 region, justifying further investigation in this regard. Second, we 7 investigated a single polymorphism in MYH9 and did not examine the impact of MYH9 haplotypes. 8 Nevertheless, crucial strengths of our study were the analysis of the recently described MYH9 9 polymorphism in both donors and recipients, our large patient population, the long and complete follow-10 up, and the hard clinical endpoints.

In conclusion, we found that patients with an AA-genotype of the *MYH9* rs11089788 variant receiving a donor kidney with the AA-genotype have an elevated risk of late graft loss. Considering the impact of this combined genotype, our findings imply donor-recipient interactions in *MYH9* that negatively influence the long-term allograft survival of kidney allografts.

1 Disclosures

- 2 The authors declare that there are no competing interests to disclose.
- 3

4 Acknowledgments

- 5 The authors thank the members of the REGaTTA cohort (REnal GeneTics TrAnsplantation; University
- 6 Medical Center Groningen, University of Groningen, Groningen, the Netherlands): S. J. L. Bakker, J.
- 7 van den Born, M. H. de Borst, H. van Goor, J. L. Hillebrands, B. G. Hepkema, G. J. Navis and H. Snieder.
- 8 The illustrations of Figure 1 were made by Siawosh K. Eskandari.

1 References

2	1.	Ibrahim HN, Murad DN, Knoll GA: Thinking Outside the Box: Novel Kidney Protective
3		Strategies in Kidney Transplantation. Clin. J. Am. Soc. Nephrol. [Internet] 17: CJN.15070920,
4		2021 Available from: https://doi.org/10.2215/CJN.15070920 [cited 2021 May 6]
5	2.	Fiorentino M, Gallo P, Giliberti M, Colucci V, Schena A, Stallone G, Gesualdo L, Castellano G:
6		Management of patients with a failed kidney transplant: what should we do? Clin. Kidney J.
7		[Internet] 14: 98–106, 2021 Available from:
8		https://academic.oup.com/ckj/article/14/1/98/5870987 [cited 2021 May 6]
9	3.	Langewisch E, Mannon RB: Chronic Allograft Injury. Clin. J. Am. Soc. Nephrol. [Internet] 16:
10		CJN.15590920, 2021 Available from: https://doi.org/10.2215/CJN.15590920 [cited 2021 May
11		6]
12	4.	Mayrdorfer M, Liefeldt L, Wu K, Rudolph B, Zhang Q, Friedersdorff F, Lachmann N, Schmidt
13		D, Osmanodja B, Naik MG, Duettmann W, Halleck F, Merkel M, Schrezenmeier E, Waiser J,
14		Duerr M, Budde K: Exploring the Complexity of Death-Censored Kidney Allograft Failure. 1–
15		14, 2021
16	5.	Farouk S, Zhang Z, Menon MC: Non-HLA donor-recipient mismatches in kidney
17		transplantation—A stone left unturned [Internet]. Am. J. Transplant. 20: 19–24, 2020 Available
18		from: https://pubmed.ncbi.nlm.nih.gov/31550409/ [cited 2021 May 6]
19	6.	Otten HG, Joosten I, Allebes WA, van der Meer A, Hilbrands LB, Baas M, Spierings E, Hack
20		CE, van Reekum F, van Zuilen AD, Verhaar MC, Bots ML, Seelen MAJ, Sanders JSF,
21		Hepkema BG, Lambeck AJ, Bungener LB, Roozendaal C, Tilanus MGJ, Vanderlocht J,
22		Voorter CE, Wieten L, van Duijnhoven E, Gelens M, Christiaans M, van Ittersum F,
23		Nurmohamed A, Lardy NM, Swelsen WT, van Donselaar-van der Pant KAMI, van der Weerd
24		NC, ten Berge IJM, Bemelman FJ, Hoitsma AJ, de Fijter JW, Betjes MGH, Roelen DL, Claas
25		FHJ: The PROCARE consortium: Toward an improved allocation strategy for kidney allografts.
26		Transpl. Immunol. [Internet] 31: 184–190, 2014 Available from:
27		http://dx.doi.org/10.1016/j.trim.2014.09.008
28	7.	Pecci A, Ma X, Savoia A, Adelstein RS: MYH9: Structure, functions and role of non-muscle
29		myosin IIA in human disease. Gene [Internet] 664: 152–167, 2018 Available from:
30		https://pubmed.ncbi.nlm.nih.gov/29679756/ [cited 2022 Mar 11]

1	8.	Tabibzadeh N, Fleury D, Labatut D, Bridoux F, Lionet A, Jourde-Chiche N, Vrtovsnik F,
2		Schlegel N, Vanhille P: MYH9-related disorders display heterogeneous kidney involvement
3		and outcome. Clin. Kidney J. [Internet] 12: 494–502, 2018 Available from:
4		https://pubmed.ncbi.nlm.nih.gov/31384440/ [cited 2022 Mar 17]
5	9.	Kao WHL, Klag MJ, Meoni LA, Reich D, Berthier-Schaad Y, Li M, Coresh J, Patterson N,
6		Tandon A, Powe NR, Fink NE, Sadler JH, Weir MR, Abboud HE, Adler SG, Divers J, Iyengar
7		SK, Freedman BI, Kimmel PL, Knowler WC, Kohn OF, Kramp K, Leehey DJ, Nicholas SB,
8		Pahl M V., Schelling JR, Sedor JR, Thornley-Brown D, Winkler CA, Smith MW, Parekh RS: A
9		genome-wide admixture scan identifies MYH9 as a candidate locus associated with non-
10		diabetic end stage renal disease in African Americans. Nat. Genet. [Internet] 40: 1185, 2008
11		Available from: /pmc/articles/PMC2614692/ [cited 2022 Mar 11]
12	10.	Kopp JB, Smith MW, Nelson GW, Johnson RC, Freedman BI, Bowden DW, Oleksyk T,
13		McKenzie LM, Kajiyama H, Ahuja TS, Berns JS, Briggs W, Cho ME, Dart RA, Kimmel PL,
14		Korbet SM, Michel DM, Mokrzycki MH, Schelling JR, Simon E, Trachtman H, Vlahov D,
15		Winkler CA: MYH9 is a major-effect risk gene for focal segmental glomerulosclerosis. Nat.
16		Genet. [Internet] 40: 1175–1184, 2008 Available from:
17		https://pubmed.ncbi.nlm.nih.gov/18794856/ [cited 2022 Mar 11]
18	11.	Genovese G, Friedman DJ, Ross MD, Lecordier L, Uzureau P, Freedman BI, Bowden DW,
19		Langefeld CD, Oleksyk TK, Uscinski Knob AL, Bernhardy AJ, Hicks PJ, Nelson GW,
20		Vanhollebeke B, Winkler CA, Kopp JB, Pays E, Pollak MR: Association of trypanolytic ApoL1
21		variants with kidney disease in African Americans. Science [Internet] 329: 841–845, 2010
22		Available from: https://pubmed.ncbi.nlm.nih.gov/20647424/ [cited 2022 Mar 11]
23	12.	O'Seaghdha CM, Parekh RS, Hwang SJ, Li M, ttgen AK, Coresh J, Yang Q, Fox CS, Linda
24		Kao WH: The MYH9/APOL1 region and chronic kidney disease in European-Americans. Hum.
25		Mol. Genet. [Internet] 20: 2450–2456, 2011 Available from:
26		https://pubmed.ncbi.nlm.nih.gov/21429915/ [cited 2022 Mar 11]
27	13.	Cheng W, Zhou X, Zhu L, Shi S, Lv J, Liu L, Zhang H: Polymorphisms in the nonmuscle
28		myosin heavy chain 9 gene (MYH9) are associated with the progression of IgA nephropathy in
29		Chinese. Nephrol. Dial. Transplant [Internet] 26: 2544–2549, 2011 Available from:
30		https://pubmed.ncbi.nlm.nih.gov/21245129/ [cited 2022 Mar 11]

1	14.	Pattaro C, Aulchenko YS, Isaacs A, Vitart V, Hayward C, Franklin CS, Polasek O, Kolcic I,
2		Biloglav Z, Campbell S, Hastie N, Lauc G, Meitinger T, Oostra BA, Gyllensten U, Wilson JF,
3		Pichler I, Hicks AA, Campbell H, Wright AF, Rudan I, Van Duijn CM, Riegler P, Marroni F,
4		Pramstaller PP: Genome-wide linkage analysis of serum creatinine in three isolated European
5		populations. Kidney Int. [Internet] 76: 297–306, 2009 Available from:
6		https://pubmed.ncbi.nlm.nih.gov/19387472/ [cited 2022 Mar 7]
7	15.	Voskarides K, Demosthenous P, Papazachariou L, Arsali M, Athanasiou Y, Zavros M,
8		Stylianou K, Xydakis D, Daphnis E, Gale DP, Maxwell PH, Elia A, Pattaro C, Pierides A, Deltas
9		C: Epistatic role of the MYH9/APOL1 region on familial hematuria genes. PLoS One [Internet]
10		8: 2013 Available from: https://pubmed.ncbi.nlm.nih.gov/23516419/ [cited 2022 Mar 11]
11	16.	Poppelaars F, Gaya Da Costa M, Eskandari SK, Damman J, Seelen MA 5: Donor genetic
12		variants in interleukin-6 and interleukin-6 receptor associate with biopsy-proven rejection
13		following kidney transplantation. medRxiv [Internet] 2021.04.17.21255669, 2021 Available
14		from: https://doi.org/10.1101/2021.04.17.21255669 [cited 2021 May 31]
15	17.	Poppelaars F, Gaya da Costa M, Faria B, Eskandari SK, Damman J, Seelen MA: A functional
16		TGFB1 polymorphism in the donor associates with long-term graft survival after kidney
17		transplantation. Clin. Kidney J. [Internet] 2021 Available from:
18		https://academic.oup.com/ckj/advance-article/doi/10.1093/ckj/sfab175/6371866 [cited 2021
19		Dec 21]
20	18.	Poppelaars F, Costa MG da, Faria B, Eskandari SK, Seelen MA, Damman J: Tumor necrosis
21		factor- α gene polymorphism is associated with short- and long-term kidney allograft outcomes.
22		medRxiv [Internet] 2021.07.28.21261294, 2021 Available from:
23		https://www.medrxiv.org/content/10.1101/2021.07.28.21261294v1 [cited 2021 Dec 21]
24	19.	Damman J, Kok JL, Snieder H, Leuvenink HG, Van Goor H, Hillebrands JL, Van Dijk MC,
25		Hepkema BG, Reznichenko A, Van den Born J, De Borst MH, Bakker SJ, Navis GJ, Ploeg RJ,
26		Seelen MA: Lectin complement pathway gene profile of the donor and recipient does not
27		influence graft outcome after kidney transplantation. Mol. Immunol. [Internet] 50: 1–8, 2012
28		Available from: http://dx.doi.org/10.1016/j.molimm.2011.11.009
29	20.	Damman J, Nijboer WN, Schuurs T a., Leuvenink HG, Morariu AM, Tullius SG, Van Goor H,
30		Ploeg RJ, Seelen M a.: Local renal complement C3 induction by donor brain death is

1 associated with reduced renal allograft function after transplantation. Nephrol. Dial. Transplant. 2 [Internet] 26: 2345–2354, 2011 Available from: http://www.ncbi.nlm.nih.gov/pubmed/21127132 3 [cited 2016 Jun 29] 4 21. Dessing MC, Kers J, Damman J, Navis GJ, Florquin S, Leemans JC: Donor and recipient 5 genetic variants in NLRP3 associate with early acute rejection following kidney transplantation. 6 Sci. Rep. 6: 2016 7 22. Auton A, Abecasis GR, Altshuler DM, Durbin RM, Bentley DR, Chakravarti A, Clark AG, 8 Donnelly P, Eichler EE, Flicek P, Gabriel SB, Gibbs RA, Green ED, Hurles ME, Knoppers BM, 9 Korbel JO, Lander ES, Lee C, Lehrach H, Mardis ER, Marth GT, McVean GA, Nickerson DA, 10 Schmidt JP, Sherry ST, Wang J, Wilson RK, Boerwinkle E, Doddapaneni H, Han Y, Korchina 11 V, Kovar C, Lee S, Muzny D, Reid JG, Zhu Y, Chang Y, Feng Q, Fang X, Guo X, Jian M, Jiang 12 H, Jin X, Lan T, Li G, Li J, Li Y, Liu S, Liu X, Lu Y, Ma X, Tang M, Wang B, Wang G, Wu H, 13 Wu R, Xu X, Yin Y, Zhang D, Zhang W, Zhao J, Zhao M, Zheng X, Gupta N, Gharani N, Toji 14 LH, Gerry NP, Resch AM, Barker J, Clarke L, Gil L, Hunt SE, Kelman G, Kulesha E, Leinonen 15 R, McLaren WM, Radhakrishnan R, Roa A, Smirnov D, Smith RE, Streeter I, Thormann A, 16 Toneva I, Vaughan B, Zheng-Bradley X, Grocock R, Humphray S, James T, Kingsbury Z, 17 Sudbrak R, Albrecht MW, Amstislavskiy VS, Borodina TA, Lienhard M, Mertes F, Sultan M, 18 Timmermann B, Yaspo ML, Fulton L, Ananiev V, Belaia Z, Beloslyudtsev D, Bouk N, Chen C, 19 Church D, Cohen R, Cook C, Garner J, Hefferon T, Kimelman M, Liu C, Lopez J, Meric P, 20 O'Sullivan C, Ostapchuk Y, Phan L, Ponomarov S, Schneider V, Shekhtman E, Sirotkin K, 21 Slotta D, Zhang H, Balasubramaniam S, Burton J, Danecek P, Keane TM, Kolb-Kokocinski A, 22 McCarthy S, Stalker J, Quail M, Davies CJ, Gollub J, Webster T, Wong B, Zhan Y, Campbell 23 CL, Kong Y, Marcketta A, Yu F, Antunes L, Bainbridge M, Sabo A, Huang Z, Coin LJM, Fang 24 L, Li Q, Li Z, Lin H, Liu B, Luo R, Shao H, Xie Y, Ye C, Yu C, Zhang F, Zheng H, Zhu H, Alkan 25 C, Dal E, Kahveci F, Garrison EP, Kural D, Lee WP, Leong WF, Stromberg M, Ward AN, Wu 26 J, Zhang M, Daly MJ, DePristo MA, Handsaker RE, Banks E, Bhatia G, Del Angel G, 27 Genovese G, Li H, Kashin S, McCarroll SA, Nemesh JC, Poplin RE, Yoon SC, Lihm J, 28 Makarov V. Gottipati S. Keinan A. Rodriguez-Flores JL. Rausch T. Fritz MH. Stütz AM. Beal K. Datta A, Herrero J, Ritchie GRS, Zerbino D, Sabeti PC, Shlyakhter I, Schaffner SF, Vitti J, 29 30 Cooper DN, Ball E V., Stenson PD, Barnes B, Bauer M, Cheetham RK, Cox A, Eberle M, Kahn

1 S, Murray L, Peden J, Shaw R, Kenny EE, Batzer MA, Konkel MK, Walker JA, MacArthur DG, 2 Lek M, Herwig R, Ding L, Koboldt DC, Larson D, Ye K, Gravel S, Swaroop A, Chew E, 3 Lappalainen T, Erlich Y, Gymrek M, Willems TF, Simpson JT, Shriver MD, Rosenfeld JA, 4 Bustamante CD, Montgomery SB, De La Vega FM, Byrnes JK, Carroll AW, DeGorter MK, 5 Lacroute P, Maples BK, Martin AR, Moreno-Estrada A, Shringarpure SS, Zakharia F, Halperin 6 E, Baran Y, Cerveira E, Hwang J, Malhotra A, Plewczynski D, Radew K, Romanovitch M, 7 Zhang C, Hyland FCL, Craig DW, Christoforides A, Homer N, Izatt T, Kurdoglu AA, Sinari SA, 8 Squire K, Xiao C, Sebat J, Antaki D, Gujral M, Noor A, Ye K, Burchard EG, Hernandez RD, 9 Gignoux CR, Haussler D, Katzman SJ, Kent WJ, Howie B, Ruiz-Linares A, Dermitzakis ET, 10 Devine SE, Kang HM, Kidd JM, Blackwell T, Caron S, Chen W, Emery S, Fritsche L, 11 Fuchsberger C, Jun G, Li B, Lyons R, Scheller C, Sidore C, Song S, Sliwerska E, Taliun D, 12 Tan A, Welch R, Wing MK, Zhan X, Awadalla P, Hodgkinson A, Li Y, Shi X, Quitadamo A, 13 Lunter G, Marchini JL, Myers S, Churchhouse C, Delaneau O, Gupta-Hinch A, Kretzschmar 14 W, Igbal Z, Mathieson I, Menelaou A, Rimmer A, Xifara DK, Oleksyk TK, Fu Y, Liu X, Xiong M, 15 Jorde L, Witherspoon D, Xing J, Browning BL, Browning SR, Hormozdiari F, Sudmant PH, 16 Khurana E, Tyler-Smith C, Albers CA, Ayub Q, Chen Y, Colonna V, Jostins L, Walter K, Xue Y, 17 Gerstein MB, Abyzov A, Balasubramanian S, Chen J, Clarke D, Fu Y, Harmanci AO, Jin M, 18 Lee D, Liu J, Mu XJ, Zhang J, Zhang Y, Hartl C, Shakir K, Degenhardt J, Meiers S, Raeder B, 19 Casale FP, Stegle O, Lameijer EW, Hall I, Bafna V, Michaelson J, Gardner EJ, Mills RE, 20 Dayama G, Chen K, Fan X, Chong Z, Chen T, Chaisson MJ, Huddleston J, Malig M, Nelson 21 BJ, Parrish NF, Blackburne B, Lindsay SJ, Ning Z, Zhang Y, Lam H, Sisu C, Challis D, Evani 22 US, Lu J, Nagaswamy U, Yu J, Li W, Habegger L, Yu H, Cunningham F, Dunham I, Lage K, 23 Jespersen JB, Horn H, Kim D, Desalle R, Narechania A, Sayres MAW, Mendez FL, Poznik 24 GD, Underhill PA, Mittelman D, Banerjee R, Cerezo M, Fitzgerald TW, Louzada S, Massaia A, 25 Yang F, Kalra D, Hale W, Dan X, Barnes KC, Beiswanger C, Cai H, Cao H, Henn B, Jones D, 26 Kave JS, Kent A, Kerasidou A, Mathias R, Ossorio PN, Parker M, Rotimi CN, Royal CD, 27 Sandoval K, Su Y, Tian Z, Tishkoff S, Via M, Wang Y, Yang H, Yang L, Zhu J, Bodmer W, 28 Bedoya G, Cai Z, Gao Y, Chu J, Peltonen L, Garcia-Montero A, Orfao A, Dutil J, Martinez-29 Cruzado JC, Mathias RA, Hennis A, Watson H, McKenzie C, Qadri F, LaRocque R, Deng X, 30 Asogun D, Folarin O, Happi C, Omoniwa O, Stremlau M, Tariyal R, Jallow M, Joof FS, Corrah

1		T, Rockett K, Kwiatkowski D, Kooner J, Hien TT, Dunstan SJ, ThuyHang N, Fonnie R, Garry
2		R, Kanneh L, Moses L, Schieffelin J, Grant DS, Gallo C, Poletti G, Saleheen D, Rasheed A,
3		Brooks LD, Felsenfeld AL, McEwen JE, Vaydylevich Y, Duncanson A, Dunn M, Schloss JA: A
4		global reference for human genetic variation. Nature. 526: 68–74, 2015
5	23.	Montgomery RA, Tatapudi VS, Leffell MS, Zachary AA: HLA in transplantation. Nat. Rev.
6		Nephrol. 14: 558–570, 2018
7	24.	Zanoni F, Kiryluk K: Genetic background and transplantation outcomes: Insights from genome-
8		wide association studies [Internet]. Curr. Opin. Organ Transplant. 25: 35–41, 2020 Available
9		from: https://pubmed.ncbi.nlm.nih.gov/31815792/ [cited 2021 May 6]
10	25.	Yang JYC, Sarwal MM: Transplant genetics and genomics. Nat. Rev. Genet. 18: 309–326,
11		2017
12	26.	Pazik J, Lewandowski Z, Oldak M, Oziębło D, Perkowska Ptasinska A, Sadowska A,
13		Nowacka-Cieciura E, Nowaczyk M, Malejczyk J, Kwiatkowski A, Durlik M: Association of
14		MYH9 rs3752462 and rs5756168 Polymorphisms With Transplanted Kidney Artery Stenosis.
15		Transplant. Proc. [Internet] 48: 1561–1565, 2016 Available from:
16		https://pubmed.ncbi.nlm.nih.gov/27496447/ [cited 2022 Mar 12]
17	27.	Franceschini N, Voruganti VS, Haack K, Almasy L, Laston S, Göring HHH, Umans JG, Lee
18		ET, Best LG, Fabsitz RR, MacCluer JW, Howard B V., North KE, Cole SA: The association of
19		the MYH9 gene and kidney outcomes in American Indians: the Strong Heart Family Study.
20		Hum. Genet. [Internet] 127: 295, 2010 Available from: /pmc/articles/PMC2930187/ [cited 2022
21		Mar 12]
22	28.	Zhang Y, Conti MA, Malide D, Dong F, Wang A, Shmist YA, Liu C, Zerfas P, Daniels MP,
23		Chan CC, Kozin E, Kachar B, Kelley MJ, Kopp JB, Adelstein RS: Mouse models of MYH9-
24		related disease: mutations in nonmuscle myosin II-A. <i>Blood</i> [Internet] 119: 238–250, 2012
25		Available from: https://pubmed.ncbi.nlm.nih.gov/21908426/ [cited 2022 Mar 12]
26	29.	Müller T, Rumpel E, Hradetzky S, Bollig F, Wegner H, Blumenthal A, Greinacher A, Endlich K,
27		Endlich N: Non-muscle myosin IIA is required for the development of the zebrafish glomerulus.
28		Kidney Int. [Internet] 80: 1055–1063, 2011 Available from:
29		https://pubmed.ncbi.nlm.nih.gov/21849970/ [cited 2022 Mar 12]
30	30.	Noris M, Remuzzi G: Non-muscle myosins and the podocyte. Clin. Kidney J. [Internet] 5: 94,

1		2012 Available from: /pmc/articles/PMC5783220/ [cited 2022 Mar 12]
2	31.	Babayeva S, Miller M, Zilber Y, Kares R El, Bernard C, Bitzan M, Goodyer P, Torban E:
3		Plasma from a case of recurrent idiopathic FSGS perturbs non-muscle myosin IIA (MYH9
4		protein) in human podocytes. <i>Pediatr. Nephrol.</i> [Internet] 26: 1071–1081, 2011 Available from:
5		https://pubmed.ncbi.nlm.nih.gov/21380797/ [cited 2022 Mar 12]
6	32.	Freedman BI, Nagaraj SK, Lin JJ, Gautreaux MD, Bowden DW, Iskandar SS, Stratta RJ,
7		Rogers J, Hartmann EL, Farney AC, Reeves-Daniel AM: Potential donor-recipient MYH9
8		genotype interactions in posttransplant nephrotic syndrome after pediatric kidney
9		transplantation. Am. J. Transplant [Internet] 9: 2435–2440, 2009 Available from:
10		https://pubmed.ncbi.nlm.nih.gov/19764949/ [cited 2022 Mar 12]
11		
12		

1 Tables

1 Table 1: Baseline characteristics of the donors and recipients

		All Patients	Functioning graft	Graft loss	D.volue*	ЦВ	D volue#
		(n = 1271)	(n = 1056)	(n = 215)	P-value	пк	P-value"
Donor							
	CC, n (%)	317 (25.0)	264 (25.0)	53 (24.8)			
MYH9 SNP	CA, n (%)	687 (54.1)	572 (54.2)	115 (53.7)	0.97		0.98
	AA, n (%)	265 (20.9)	219 (20.8)	46 (21.5)			
Age, years		44.4 ± 14.4	44.1 ± 14.6	46.1 ± 13.4	0.044	1.02	<0.001
Male sex, n (%)		645 (50.7)	535 (50.7)	110 (51.2)	0.89		0.96
Blood group							
Type O, n (%)		642 (50.5)	541 (51.3)	101 (47.2)		0.39	0.004
Type A, n (%)		502 (39.5)	414 (39.3)	88 (41.1)	0 033	0.42	0.01
Type B, n (%)		97 (7.6)	82 (7.8)	15 (7.0)	0.000	0.36	0.012
Type AB, n (%)		27 (2.1)	17 (1.6)	10 (4.7)		Ref	0.035
Donor type							
Living, n (%)		282 (22.2)	257 (24.3)	25 (11.6)		Ref	
Brain death, n (%	5)	787 (61.9)	642 (60.8)	145 (67.4)	<0.001	1 94	0.002
Circulatory death	, n (%)	202 (15.9)	157 (14.9)	45 (20.9)		1.01	
Recipient							
	CC, n (%)	326 (25.7)	270 (25.6)	56 (26.2)			
MYH9 SNP	CA, n (%)	635 (50.0)	539 (51.1)	96 (44.9)	0.15		0.31
	AA, n (%)	308 (24.3)	246 (23.3)	62 (29.0)			
Age, years		47.9 ± 13.5	48.5 ± 13.4	45.0 ± 13.2	<0.001	0.99	0.027
Male sex, n (%)		739 (58.1)	607 (57.5)	132 (61.4)	0.29		0.21
Primary kidney	disease	- · · · · · · · · · · · · · · · · · · ·				1	
Glomerulonephritis, n (%)		340 (26.8)	271 (25.6)	69 (32.2)			
Polycystic diseas	e, n (%)	208 (16.4)	188 (17.8)	20 (9.3)			
Vascular disease, n (%)		145 (9.9)	123 (11.6)	22 (10.3)			
Pyelonephritis, n (%)		148 (11.4)	120 (11.4)	28 (13.1)	0.28		0.45
Diabetes, n (%)		51 (4.0)	44 (4.2)	7 (3.3)			
Idiopathic, n (%)		168 (13.2)	134 (12.7)	34 (15.9)			
Other, n (%)		211 (16.6)	177 (16.7)	34 (15.9)			
Blood group		F07 (44 0)	474 (44.0)	00 (40 0)		0.40	
Type O, n (%)		567 (44.6)	474 (44.9)	93 (43.3)		0.46	0.002
Type A, n (%)		536 (42.2)	448 (42.4)	88 (40.9)	0.004	0.46	0.002
Type B, n (%)		113 (8.9)	98 (9.3)	15 (7.0)		0.35	0.002
Type AB, n (%)	waaka	55 (4.3)	36 (3.4)	19 (8.8)	0.15	Ref	0.008
Dialysis vintage,	Weeks	172 [91 - 203]	1/4 [87 - 201]	108 [109 - 270]	0.15		0.10
Highest PRA, In	% 	10.1 ± 23.0	10.0 ± 23.3	10.9 ± 25.0	0.60		0.75
Anti CD3 Mooh	sion p (%)	10 (1 5)	11 (1 2)	5 (2 2)	0.27		0.51
Anti-CD3 Moab, n (%)		19 (1.3)	70 (7.5)	5 (2.3) 24 (11.2)	0.27		0.51
AIG, n (%)		103 (0.1)	<u> </u>	24 (11.2)	0.07		0.14
Azathioprine, n (%)		12(0.7)	1002 (04 0)	19 (0.0)	0.027	0.51	0.29
Concesteroids, II (%)		1201 (94.3)	011 (96.3)	199 (92.0)	0.17	0.51	0.01
Interleukin-2 RA n (%)		1005 (05.4)	163 (15 4)	36 (16 7)	0.044	0.00	0.010
Mycophenolic acid n (%)		907(714)	775 (73.4)	132 (61 4)	<0.03		0.12
Sirolimus n (%)		38 (3 0)	33 (3 1)	5 (2 3)	0.53	<u> </u>	0.00
		07 (7.6)	77 (7 3)	20 (0.3)	0.33		0.34
Transplantation		91 (1.0)	(1.3)	20 (9.3)	0.01		0.03
		177[10 0 22 0]	170 [86 220]	20.0 [15.2 25.0]	<0.001	1.02	0.004
WIT in minutes		37.0[31 45]	37.0 [30 45]	20,0 [10.0 - 20.0]	0.12	1.03	0.001
		$2[1 \ 2]$	2 [1 2]	$2[1 \ 2]$	0.12	1.02	0.003
		∠ [1 − 3] 415 (22 7)	2 [1 - J]	2 [1 - 3] 126 (59 6)	0.40	2 70	<0.01
		413 (32.7)	209 (21.4)	120 (00.0)	NU.UU 1	3.19	NU.UU 1

2 Data are displayed as mean ± standard deviation for parametric variables; median [IQR] for non-

3 parametric variables, and nominal data as the total number of patients with the corresponding

1 percentage [n (%)]. MYH9, non-muscle myosin heavy chain 9 gene; PRA, panel-reactive antibody; 2 CD3, cluster of differentiation 3; ATG, Anti-thymocyte globulin; RA, receptor antagonist; CIT, cold 3 ischemia time; WIT, warm ischemia time; HLA, human leukocyte antigen; DGF, delayed graft function. 4 Bold values are used to show which testing was statistically significant (P-value < 0.05) 5 P-value* indicates the P-value for the differences in baseline characteristics between the groups, 6 tested by Student's *t*-test or the Mann–Whitney U-test for continuous variables, with the χ^2 test for 7 categorical variables. 8 P-value[#] indicates the P-value for univariable analysis with 15-year death censored graft survival.

1 **Table 2**

2 Logistic regression analysis for the risk of delayed graft function after kidney transplantation

Variables	P-value	Hazard Ratio
MYH9 rs111089788 SNP in the recipient (AA <i>versus</i> CA/CC)	0.15	1.26 (0.92 – 1.72)
Donor age <i>(in years)</i>	<0.001	1.02 (1.01 – 1.03)
Donor gender (<i>male versus female</i>)	0.001	1.61 (1.22 – 2.13)
Donor type (deceased versus living)	0.001	31.61 (4.14 – 214.57)
Total HLA mismatches	0.006	1.16 (1.04 – 1.30)
Dialysis vintage <i>(in years)</i>	0.007	1.08 (1.02 – 1.14)
Warm ischemia time (<i>in minutes</i>)	0.020	1.01 (1.00 – 1.03)
Recipient age (in years)	0.44	1.00 (0.99 – 1.02)
Cold ischemia time (<i>in minutes</i>)	0.47	1.00 (1.00 – 1.00)

3

Multivariable logistic regression was performed for delayed graft function after kidney transplantation.
Only variables with a *P* < 0.05 in the univariable analysis were included. Data are presented as an odds</p>
ratio with a 95% confidence interval (CI) and *P*-value. Donor age, donor gender, donor type, total HLA
mismatches, dialysis vintage, and warm ischemia time were significant, whereas the *MYH9* SNP
(rs11089788) in the recipient, recipient age, and cold ischemia time were not.

1 **Table 3**

2 Multivariable analysis for the risk of biopsy-proven acute rejection after kidney transplantation

Variables	P-value	Hazard Ratio
<i>MYH9</i> rs111089788 SNP in the recipient (AA <i>versus</i> CA/CC)	0.10	1.22 (0.97 – 1.54)
Recipient age <i>(in years)</i>	<0.001	0.97 (0.97 – 0.98)
Total HLA mismatches	<0.001	1.20 (1.11 – 1.29)
Delayed graft function (yes versus no)	0.015	1.31 (1.05 – 1.62)
Recipient gender (female versus male)	0.039	1.25 (1.01 – 1.55)
Warm ischemia time (<i>in minutes</i>)	0.08	0.99 (0.98 – 1.00)

3

Multivariable Cox regression was performed for biopsy-proven acute rejection (BPAR) after kidney transplantation. Only variables with a *P* < 0.05 in the univariable analysis were included. Data are presented as a hazard ratio with a 95% confidence interval (CI) and *P*-value. Recipient age, total HLA mismatches, delayed graft function (DGF), and recipient gender were significant, whereas the *MYH9* SNP (rs11089788) in the recipient and warm ischemia time were not.

- 1 **Table 4**
- 2 Associations of non-muscle myosin heavy chain 9 polymorphism in donor-recipient pairs with
- 3 graft loss after kidney transplantation.

	MYH9 SNP (rs1800472) in donor-recipient pairs			
	Hazard ratio (AA+AA vs. <i>others</i>)	95% CI	<i>P</i> -value	
Model 1	1.78	1.13 – 2.79	0.012	
Model 2	1.90	1.19 – 3.02	0.007	
Model 3	1.95	1.24 – 3.08	0.004	
Model 4	1.91	1.16 – 3.12	0.011	

4

- 5 Data are presented as a hazard ratio with a 95% confidence interval (CI) and *P*-value.
- 6 **Model 1:** Crude model.

7 Model 2: Adjusted for model 1 plus recipient characteristics: Recipient age, recipient sex, recipient

8 blood type, and dialysis vintage.

9 **Model 3:** Adjusted for model 1 plus donor characteristics: Donor age, donor sex, donor blood type, and

10 donor origin.

11 **Model 4:** Adjusted for model 1 plus transplant characteristics: Cold and warm ischemia time, and the

12 number of human leukocyte antigen (HLA)-mismatches.

1 **Table 5**

2 Multivariable analysis for the risk of graft loss after renal transplantation

Variables	P-value	Hazard Ratio		
rs111089788 in donor-recipient pairs	0.031	1.68 (1.05 – 2.70)		
(AA+AA versus others)				
Delayed graft function	<0.001	3 17 (2 56 1 72)		
<i>(yes</i> versus <i>no)</i>	~0.001	3.47 (2.50 - 4.72)		
Recipient age	10.001			
(in years)	<0.001	0.98 (0.97 – 0.99)		
Donor age	0.001	1.02(1.01 - 1.03)		
(in years)	0.001	1.02 (1.01 – 1.03)		
Recipient blood type	0.061			
(AB versus other)	0.001			
Warm ischemia time	0.40			
(in minutes)	0.12	1.01 (1.00 – 1.02)		
Corticosteroids	0.20	1.53 (0.80 – 2.95)		
Cold ischemia time	0.00			
(in minutes)	0.32	1.00 (1.00 – 1.00)		
Donor type	0.44			
(living versus deceased)	0.41	0.76 (0.39 – 1.46)		
Cyclosporin A	0.71	1.04 (0.71 – 1.66)		
Donor blood type	0.00			
(AB versus other)	0.90			

³

Multivariable cox regression was performed for kidney graft survival. Only variables with a *P* < 0.05 in the univariable analysis were included. Data are presented as a hazard ratio with a 95% confidence interval (CI) and *P*-value. In the final model, the *MYH9* SNP (rs11089788) in donor-recipient pairs, the occurrence of delayed graft function, recipient age, and donor age were significant, whereas recipient blood type, warm ischemia time, use of corticosteroids, cold ischemia time, donor type, use of cyclosporin A, and donor blood type were not.

- 1 Figures
- 2

5

- 3 Figure 1
- 4 Illustration of the non-muscle myosin heavy chain 9 and the examined *MYH9* polymorphisms.



6 (A) Non-muscle myosin heavy chain II-A (MHCII-A) is a contractile protein comprised of several 7 domains: A globular motor head portion (heavy chain), a neck domain (essential light chain and 8 regulatory light chain), coiled coil tail segment (MHCII-A), and non-helical tailpiece that can be 9 phosphorylated. The coiled coil segment is notably encoded by the myosin heavy chain 9 (MYH9) gene. 10 (B) In this study, we assessed the association of rs11089788 (C>A) MYH9 single-nucleotide 11 polymorphism (SNPs) in kidney allograft donors and recipients with long-term graft survival outcomes. 12 MHCII-A, non-muscle heavy chain II-A; MYH9, myosin heavy chain 9 gene; SNP, single nucleotide 13 polymorphism.

- 1 **Figure 2**
- 2 Kaplan-Meier curves for rejection-free survival of kidney allografts according to the presence
- 3 of a non-muscle myosin heavy chain 9 gene polymorphism in the recipient.



⁴

- 7 the AA-genotype of the MYH9 SNP rs11089788 versus the AC/CC-genotype. Log-rank test was used
- 8 to compare the incidence of biopsy-proven rejection between the groups.
- 9

 ⁽A) Cumulative rejection-free survival of kidney allografts according to the presence of the *MYH9* SNP
 rs11089788 in the recipient. (B) Cumulative rejection-free survival of kidney allografts in recipients with

- 1 Figure 3
- 2 Kaplan-Meier curves for 15-year death-censored kidney graft survival according to the presence
- 3 of a non-muscle myosin heavy chain 9 gene polymorphism in the donor or recipient.



4

(A) Cumulative 15-year death-censored kidney graft survival according to the presence of a genetic
variant in non-muscle myosin heavy chain 9 gene (*MYH9*, rs11089788 C>A) in (A, B) the recipient (blue
line) or (C) the donor (yellow line). (B) Cumulative 15-year death-censored graft survival of kidney
allografts in recipients with the AA-genotype of the *MYH9* SNP rs11089788 versus the AC/CC-genotype.
Log-rank test was used to compare the incidence of graft loss between the groups.

- 1 Figure 4
- 2 Kaplan-Meier curves for 15-year death-censored kidney graft survival according to the presence
- 3 of a non-muscle myosin heavy chain 9 gene polymorphism in donor-recipient pairs.



4

5 Cumulative 15-year death-censored kidney graft survival is shown according to the presence of the 6 *MYH9* polymorphism in donor-recipient pairs. (**A**) Pairs were divided into four groups according to the 7 absence (black line) or presence of the AA-genotype in the recipient (blue line), donor (yellow line), or 8 both (green line). (**B**) In addition, the presence of the AA-genotype in both the recipient and donor 9 (green line) was compared to the rest (black line). Log-rank test was used to compare the incidence of 10 graft loss between the groups.